AstraZeneca’s Corona 19 Vaccine (CG)The chief executive officer (CEO) of the multinational pharmaceutical company AstraZeneca said on the 9th (local time) that the company’s novel coronavirus infection (Corona 19) vaccine is effective for severely ill patients, Reuters reported.
At the World Health Organization (WHO) meeting that day, CEO Pascal Sorio said, “Of course, that is a concern” for a study that the AstraZeneca vaccine is limited in preventing the mild and moderate onset of the corona 19 mutant virus from South Africa .
But, he stressed, “we believe the vaccine still prevents severe outbreaks.”
Previously, in the Phase 1 and 2 clinical trials conducted by the University of South Africa and Oxford University in the UK, 2,26 people were given the AstraZeneca vaccine twice, which could not prevent mild and moderate symptoms due to mutations in South Africa. Appeared.
Based on the results of these clinical trials, the South African government recently decided to withhold the use of the AstraZeneca vaccine.
However,’CoVax Facility’, an international project for joint purchase and distribution of the Corona 19 vaccine, said that there is currently no plan to reject the vaccine, as studies on the preventive effect of the AstraZeneca vaccine against the Corona 19 mutation are still ongoing.
AstraZeneca is a major vaccine supplier of COVAX, led by the WHO, the Global Vaccine Immunization Association (Gavi), and the Infectious Disease Innovation Association (CEPI).
KOVAX plans to deliver 366 million doses of AstraZeneca vaccine to member countries in the first half of this year.
[연합뉴스]
Copyrights ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited